Veracyte, Inc. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 14.0% margin the price requires 12.1% 3y revenue CAGR against 10.3% consensus, a cushion of -8.5pt versus a 0pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. Unaffected.
Would recover if: reimbursement or dilution keeps margin well below 21.6% consensus. We re-check this against analyst estimates every evening.
10 years, at a 14% margin analysts expect
+7.1%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
11 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 887% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 24, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price at the price sits at the very bottom of the published model range ($44 to $69), rejecting eight bull cases and fully endorsing only the view that growth will decelerate to the high-single digits.
Does the launch of Prosigna and TrueMRD actually accelerate revenue growth back above the roughly 9% the price requires, and the wired data can only partially settle this by tracking overall unit volumes rather than product-specific adoption.
What the price refuses to pay for, and the full reconstruction, on the VCYT quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names